HRP20181672T1 - Kondenzirani bicklički (hetero)aromatski spojevi pogodni za liječenje karcinoma - Google Patents
Kondenzirani bicklički (hetero)aromatski spojevi pogodni za liječenje karcinomaInfo
- Publication number
- HRP20181672T1 HRP20181672T1 HRP20181672TT HRP20181672T HRP20181672T1 HR P20181672 T1 HRP20181672 T1 HR P20181672T1 HR P20181672T T HRP20181672T T HR P20181672TT HR P20181672 T HRP20181672 T HR P20181672T HR P20181672 T1 HRP20181672 T1 HR P20181672T1
- Authority
- HR
- Croatia
- Prior art keywords
- bicklic
- hetero
- condensed
- aromatic compounds
- compounds suitable
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1416186.3A GB201416186D0 (en) | 2014-09-12 | 2014-09-12 | Compounds |
| EP15766218.0A EP3191477B1 (de) | 2014-09-12 | 2015-09-11 | Zur behandlung von krebserkrankungen geeignete kondensierte (hetero)bicyclische verbindungen |
| PCT/GB2015/052640 WO2016038389A1 (en) | 2014-09-12 | 2015-09-11 | Fused bicyclic (hetero)aromatic compounds useful for the treatment of cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20181672T1 true HRP20181672T1 (hr) | 2019-02-08 |
Family
ID=51869542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20181672TT HRP20181672T1 (hr) | 2014-09-12 | 2015-09-11 | Kondenzirani bicklički (hetero)aromatski spojevi pogodni za liječenje karcinoma |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | USRE49361E1 (de) |
| EP (1) | EP3191477B1 (de) |
| JP (1) | JP6781150B2 (de) |
| CN (1) | CN107108588B (de) |
| AU (1) | AU2015314007B2 (de) |
| CA (1) | CA2960477C (de) |
| DK (1) | DK3191477T3 (de) |
| ES (1) | ES2702477T3 (de) |
| GB (1) | GB201416186D0 (de) |
| HR (1) | HRP20181672T1 (de) |
| HU (1) | HUE041751T2 (de) |
| WO (1) | WO2016038389A1 (de) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12478604B1 (en) | 2016-07-22 | 2025-11-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| EP3930702A1 (de) | 2019-03-01 | 2022-01-05 | Flamel Ireland Limited | Gamma-hydroxybutyratzusammensetzungen mit verbesserter pharmakokinetik im zugeführten zustand |
| IL300110A (en) * | 2020-07-28 | 2023-03-01 | Jazz Pharmaceuticals Ireland Ltd | Chiral synthesis of fused bicyclic raf inhibitors |
| EP4188552A2 (de) | 2020-07-28 | 2023-06-07 | Jazz Pharmaceuticals Ireland Limited | Kondensierte bicyclische raf-hemmer und verfahren zur verwendung davon |
| JP2024504285A (ja) * | 2020-12-29 | 2024-01-31 | ティーエックスイノ バイオサイエンス インコーポレイテッド | エクトヌクレオチドピロホスファターゼ－ホスホジエステラーゼの阻害活性を有する新規のナフチリジノン誘導体及びこれらの用途 |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| TW202421110A (zh) | 2022-11-29 | 2024-06-01 | 愛爾蘭商爵士製藥愛爾蘭有限責任公司 | （ｓ）－５－（（３－〈４－〈４－氟苯基）－１ｈ－咪唑－２－基）色滿－６－基）氧基）－３，４－二氫－１，８－萘啶－２（１ｈ）－酮之結晶形式 |
| AU2024223957A1 (en) * | 2023-02-17 | 2025-09-04 | Jazz Pharmaceuticals Ireland Limited | Methods of treating solid tumors with mitogen activated protein kinase (mapk) pathway alterations |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5698550A (en) * | 1993-06-14 | 1997-12-16 | Pfizer Inc. | Tetralin and chroman derivatives useful in the treatment of asthma, arthritis and related diseases |
| US6465445B1 (en) * | 1998-06-11 | 2002-10-15 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
| FI20011507A0 (fi) | 2001-07-10 | 2001-07-10 | Orion Corp | Uusia yhdisteitä |
| FI20030030A0 (fi) | 2003-01-09 | 2003-01-09 | Orion Corp | Uusia yhdisteitä |
| CN1690056A (zh) | 2004-04-30 | 2005-11-02 | 北京大学 | 三个化合物及其制备方法和用途 |
| GB0503506D0 (en) | 2005-02-21 | 2005-03-30 | 4 Aza Bioscience Nv | Substituted pyrido(2,3-d) pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders |
| WO2006124874A2 (en) | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Inhibitors of b-raf kinase |
| WO2007067444A1 (en) * | 2005-12-08 | 2007-06-14 | Millennium Pharmaceuticals, Inc. | Bicyclic compounds with kinase inhibitory activity |
| US10144736B2 (en) | 2006-07-20 | 2018-12-04 | Gilead Sciences, Inc. | Substituted pteridines useful for the treatment and prevention of viral infections |
| PL2797888T3 (pl) * | 2011-12-31 | 2016-12-30 | Połączone związki tricykliczne jako inhibitory kinazy raf |
-
2014
- 2014-09-12 GB GBGB1416186.3A patent/GB201416186D0/en not_active Ceased
-
2015
- 2015-09-11 CN CN201580061422.2A patent/CN107108588B/zh active Active
- 2015-09-11 HU HUE15766218A patent/HUE041751T2/hu unknown
- 2015-09-11 JP JP2017513631A patent/JP6781150B2/ja active Active
- 2015-09-11 AU AU2015314007A patent/AU2015314007B2/en active Active
- 2015-09-11 WO PCT/GB2015/052640 patent/WO2016038389A1/en not_active Ceased
- 2015-09-11 US US17/102,621 patent/USRE49361E1/en active Active
- 2015-09-11 HR HRP20181672TT patent/HRP20181672T1/hr unknown
- 2015-09-11 US US15/509,952 patent/US10183939B2/en not_active Ceased
- 2015-09-11 EP EP15766218.0A patent/EP3191477B1/de active Active
- 2015-09-11 ES ES15766218T patent/ES2702477T3/es active Active
- 2015-09-11 CA CA2960477A patent/CA2960477C/en active Active
- 2015-09-11 DK DK15766218.0T patent/DK3191477T3/en active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016038389A1 (en) | 2016-03-17 |
| JP6781150B2 (ja) | 2020-11-04 |
| CN107108588B (zh) | 2021-06-01 |
| ES2702477T3 (es) | 2019-03-01 |
| AU2015314007A1 (en) | 2017-03-30 |
| HUE041751T2 (hu) | 2019-05-28 |
| CA2960477A1 (en) | 2016-03-17 |
| CA2960477C (en) | 2023-02-14 |
| GB201416186D0 (en) | 2014-10-29 |
| CN107108588A (zh) | 2017-08-29 |
| EP3191477A1 (de) | 2017-07-19 |
| DK3191477T3 (en) | 2018-11-05 |
| US10183939B2 (en) | 2019-01-22 |
| JP2017527586A (ja) | 2017-09-21 |
| US20170298061A1 (en) | 2017-10-19 |
| EP3191477B1 (de) | 2018-07-18 |
| USRE49361E1 (en) | 2023-01-10 |
| AU2015314007B2 (en) | 2020-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20181672T1 (hr) | Kondenzirani bicklički (hetero)aromatski spojevi pogodni za liječenje karcinoma | |
| LT3157916T (lt) | Heteroarilo junginiai, skirti kinazės inhibavimui | |
| HRP20182101T1 (hr) | Poboljšani uređaj za vaporizaciju | |
| DK3511328T3 (da) | Organiske monobactam-forbindelser til behandling af bakterieinfektioner | |
| LT3134402T (lt) | 4-amino-imidazochinolino junginiai | |
| LT3197883T (lt) | Nauji junginiai | |
| SI3594238T1 (sl) | Sestavki protiteles za zdravljenje tumorja | |
| HUE042964T2 (hu) | Szubsztituált dihidro-izokinolinon vegyületek | |
| HUE054784T2 (hu) | 5-klór-2-difluor-metoxifenil-pirazolopirimidin vegyületek, amelyek JAK-gátlók | |
| IL258684A (en) | Combination therapy for treating malignancies | |
| BR112016016792A2 (pt) | Aparelho para tratamento de vestuário | |
| IL260082B (en) | Small molecules against cancer | |
| DK3148529T3 (da) | Forbindelser til behandling af hjernecancer | |
| BR112016029361A2 (pt) | novos compostos substituídos por halogênio | |
| HUE037210T2 (hu) | Triciklusos heterociklusos vegyületek, mint foszfoinozitid 3-kináz inhibitorok | |
| LT3233813T (lt) | Į oksatiaziną panašių junginių gavimo būdai | |
| DK3122308T3 (da) | Indretning til behandling af smerte | |
| DK3157926T3 (da) | Organiske forbindelser | |
| HRP20190583T1 (hr) | Postupci za pripremu spoja diariltiohidantoina | |
| CL2016002165A1 (es) | Compuestos de aminocarbonilcarbamato | |
| MA41266A (fr) | Cataplasme | |
| LT3347360T (lt) | Junginiai, naudingi ror-gama-t slopinimui | |
| PL3341614T3 (pl) | Części obrotowe do pompy szlamowej | |
| DK3191466T3 (da) | Azetidinyloxyphenylpyrrolidinforbindelser | |
| HUE039805T2 (hu) | Új szulfonilaminobenzamid vegyületek |